The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., Oct. 18, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023. Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and […]
ABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023. Second-quarter GAAP diluted EPS of $0.78 and adjusted diluted EPS of $1.08, which excludes specified items. Projected full-year 2023 diluted EPS on a GAAP basis of $3.02 to $3.22. Projected full-year adjusted EPS of $4.30 to $4.50 remains unchanged but […]
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients CardioMEMS is a paperclip-sized sensor that can remotely flag to a patient’s clinical team the early warning signs of worsening heart failure ABBOTT PARK, Ill., May 24, 2023 /PRNewswire/ — New data presented […]
Abbott’s AVEIR™ DR i2i™ IDE study is the industry’s first prospective study on the safety and performance of the world’s first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott’s investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the […]
TactiFlex™ Ablation Catheter, Sensor Enabled™, is the world’s first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation When used with Abbott’s EnSite™ X EP System, physicians have better visualization allowing for more accuracy and precision with the TactiFlex catheter, […]
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with […]
Data presented at EuroPCR 2023 build on prior study results demonstrating TriClip is a safe and effective therapy to treat leaky tricuspid valves Findings from the largest real-world dataset for tricuspid repair show device reduces tricuspid regurgitation and improves quality of life ABBOTT PARK, Ill., May 17, 2023 — Abbott […]
Abbott’s Assert-IQ offers the world’s longest battery life† for an insertable cardiac monitor (ICM) The latest addition to Abbott’s portfolio of connected health devices, the Assert-IQ ICM offers long-term monitoring and remote programming to improve connectivity to patients The device provides continuous monitoring for abnormal heart rhythms while offering tools […]
ABBOTT PARK, Ill., April 27, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s […]
Abbott’s CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott’s CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support […]
